Spinal Muscular Atrophy Treatment Market Size Worth $3.9 Billion By 2025

The global spinal muscular atrophy (SMA) treatment market size is expected to reach USD 3.9 billion by 2025, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 12.9% during the forecast period. Due to the rare nature and complexity of these diseases, scientific knowledge pertaining to them is scarce. However, there are various initiatives undertaken to increase awareness regarding rare diseases and to support SMA communities. This is anticipated to boost market development over the coming years.

Various SMA communities and companies have collaborated for developing disease treatment therapy. For example, RG7916, which is an investigational therapy being developed by Roche in collaboration with SMA Foundation and PTC Therapeutics. Thus, heavy investments in R&D by major companies are also projected to contribute to the growth of this market. CureSMA, SMA Foundation, and SMA Europe are some of the organizations actively supporting R&D pertaining to SMA.

CureSMA provided funding to a research project to Biogen and Ionis Pharmaceuticals, Inc. for developing Spinraza, which received U.S. FDA approval in 2016. This organization has invested nearly USD 70 million in the research pertaining to SMA, which also included a planned investment of USD 5 million in the coming years.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/spinal-muscular-atrophy-sma-treatment-market

Further key findings from the study suggest:

The global spinal muscular atrophy treatment market is projected to expand at a CAGR of 12.9% over the forecast period
Based on disease type, type 1 accounted for the largest revenue share owing to the rising incidence of type 1 SMA
By treatment, the drug segment accounted for the largest revenue share in 2017
North America will retain its lead as the largest regional market; however, Asia Pacific is anticipated to register the fastest CAGR over the forecast period
The market is presently led by Biogen Inc. Biogen’s Spinraza is the only approved commercialized treatment for SMA, owing to which market is not competitive. However, this trend is expected to change after the commercialization of other treatment therapies post-2020

Specialty Generics Market Size Worth $174.9 Billion By 2025

The global specialty generics market is expected to reach USD 174.9 billion by 2025, according to a new report by Grand View Research, Inc. Rise in demand for low-cost generic specialty drugs is a major factor estimated to accelerate the market growth during the forecast period. Introduction of cost-effective drugs for the treatment of multiple sclerosis, cancer, and other infectious diseases is expected to showcase huge opportunities for the specialty generic drug manufacturers. According to U.S. FDA, generic drugs cost 80% to 85% lower as compared to branded drugs. One of the factors contributing to their affordable price is that they do not need to repeat expensive clinical trials, advertising, and promotional activities. Thus, low cost of generic specialty drugs is expected to accelerate the demand for these medicines.

Rise in number of off-patent specialty drugs is another major factor expected to support growth of the specialty generic drugs market. For instance, the patent for Gilenya, a blockbuster drug by Novartis, will expire in 2019. This drug led to USD 3.1 billion in sales in 2016 for Novartis, with 14% sales growth. In April 2017, Novartis failed to acquire patent extension for Gilenya till 2026 in the U.S. Federal Circuit. Such early patent expirations are expected to boost the entry of new generics.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/specialty-generics-market

Further Key Findings From the Report Suggest:

In 2016, injectables was the largest revenue-grossing segment in the market due to its high usage and efficacy in treatment of severe chronic diseases
The oncology segment accounted for the largest revenue share in 2016 and is expected to maintain its dominance during the forecast period due to worldwide rise in cancer prevalence
The specialty pharmacy was the largest revenue-generating segment in end use and is estimated to maintain its dominance during the forecast period. This is due to the fact that specialty pharmacies are dedicated to distribution of highlycomplex, costly, and high-touch medicine
North America dominated the total market in 2016 primarily due to the presence of highly developed healthcare infrastructure and local presence of large number of established pharmaceutical companies
The Asia Pacific market is estimated to grow at the highest growth rate during the forecast period. Rising prevalence of chronic diseases, developing healthcare infrastructure, and escalating disposable income in Asian countries, such as China and India, are major factors that can be attributed to the growth
Some of the major players are Teva Pharmaceuticals USA, Inc.; Mylan N.V.; Sandoz International GmbH; Akorn, Inc.; Mallinckrodt; Valeant Pharmaceuticals International, Inc.; Pfizer, Inc.; Endo Pharmaceuticals, Inc.; Apotex Corp.; Sun Pharmaceutical Industries Ltd.

Drug And Gene Delivery Systems Market Worth $786.9 Billion By 2025

The global drug and gene delivery systems market is expected to reach USD 786.9 Billion by 2025, according to a new report by Grand View Research, Inc. Rising investment by the market players to develop innovative drug delivery systems to cater to the demand by the patients as well as to increase the bioavailability at minimum quantity of active pharmaceutical ingredient is driving the market growth. Additionally, increasing focus on R&D of gene delivery systems owing to the high growth potential of gene therapy for the treatment of a wide range of diseases is expected to fuel the market growth in the future.

Drug delivery systems are in a constant evolution along with the changing preference by the patient. For instance, initially, hormone replacement therapy was widely prescribed in the form of pills, whereas, it is now available in the form of prefilled syringes, patches, vaginal rings, gel, and sprays. The principal purpose of development of different forms of delivery systems is to increase the ease of use. Factors such as aesthetics of the delivery systems, price, and amount of API are also considered while designing the drug delivery system.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/drug-gene-delivery-devices-market

Further key findings from the study suggest:

The market study suggests that oral segment dominated the market in 2015
The convenience of use and low manufacturing cost are the prime factors responsible for the dominance of the oral delivery segment
Injectable segment is expected to show a lucrative growth rate owing to the introduction of technically advanced injecting devices that enable convenient self-injection
North America dominated the market in 2015 and is expected to remain dominant throughout the forecast period owing to highly developed healthcare infrastructure and high healthcare spending
Asia pacific is expected to exhibit the fastest growth rate during the forecast period owing to the factors such as rapidly developing economies, growing disposable income, and high adaption of the advanced delivery systems
A few of the major market players in drug delivery systems space are F. Hoffmann-La Roche Ltd, Pfizer, Inc., Johnson and Johnson private Ltd, Novartis AG, Becton, Dickinson and Company, and Bayer AG.
Major market players in the gene delivery systems space are SiBiono GeneTech Co., Unique N.V., Epeius Biotechnologies Corporation, Human Stem Cells Institute, and Shanghai Sunway Biotech Co., Ltd.

Anti-Snoring Devices & Snoring Surgery Market Worth $1.8 Billion By 2024

Global anti-snoring devices and snoring surgery market is expected to reach USD 1.84 billion by 2024, according to a new report by Grand View Research, Inc. The anti-snoring devices and snoring surgery market is anticipated to witness a lucrative growth during the period 2016 to 2024. The factors contributing towards the growth of the market are the growing awareness levels about the ill effects of snoring, rising elderly and obese population, the presence of an unexploited consumer base, and the increasing consumption of alcohol and cigarettes. However, factors such as the cost prohibitive nature of the products, limited efficacy of the presently available treatments, and the presence of an unpropitious reimbursement scenario are likely to hinder the growth of the market.

The market is segmented into anti-snoring devices and snoring surgery segments. The anti-snoring devices segment includes oral appliances, nasal devices, position control devices, chin straps, tongue stabilizing devices, and expiratory positive airway pressure therapy devices. The surgery segment includes uvulopalatopharyngoplasty, laser-assisted uvulopalatoplasty, radiofrequency ablation, sclerotherapy, pillar procedure, and others. North America and Europe are the major shareholders of this industry due mainly to the increasing awareness associated with available treatment options and the eventual rise in popularity and adoption of these products. The Asia Pacific region is expected to witness high growth as a consequence of the untapped population base characterized with a snoring condition, higher levels of awareness regarding the effects of snoring, and the presence of well-established players in the sector.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/anti-snoring-devices-snoring-surgery-market

Further key findings from the study suggest:

North America is estimated to lead the industry with the largest market share in 2015.This growth is attributed to the rapidly increasing popularity and the resultant high market penetration of such treatment devices. Asia Pacific is expected to exhibit the highest growth rate owing to the large untreated population and the rising awareness levels with regard to treatment options and the notorious health consequences associated with this condition.
In surgery, somnoplasty is estimated to be the fastest growing segment due largely to factors, such as low cost, reduced surgical trauma, less invasive, and chances of fewer complications in comparison to the traditional surgery procedures
The anti-snoring devices and snoring surgery market comprises several local as well as global players. Some key market players include Tomed Dr. Toussaint GmbH, Apnea Sciences Corporation, and Meditas Ltd., among others. The companies have adopted several organic and inorganic strategies in order to gain prominence in this sector. A few of these strategies include geographic expansion, new product launches, new product development, partnerships, collaborations, and mergers and acquisitions, among others. For instance, in March 2015, Meditas Ltd. launched nasal dilators for uninterrupted flow of air.

Aminoglycoside Market Size To Reach $1.68 Billion By 2022

Global aminoglycoside market is expected to reach USD 1.68 billion by 2022 growing at an estimated CAGR of 3.5% from 2015 to 2022, according to a new report by Grand View Research, Inc. This expected growth in demand can be ascribed to the increasing incidences of animal disease outbreaks leading to high utilization of antibiotics.

However, reduction in prescription rate of aminoglycoside antibiotics due to side effects associated with usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade are expected to affect the market growth negatively. Furthermore, regulatory disapproval for the usage of certain aminoglycoside in regions is also anticipated to attribute for subordinate growth in this industry.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/aminoglycoside-market

Further key findings from the report suggest:

Neomycin and tobramycin together contributed for over USD 600 million as revenue in this market owing to higher usage and prescription of these drugs for treatment of different bacterial infections. Neomycin finds higher usage in topical formulations for treatment of different skin infections.
Injectables accounted for the largest share of revenue amongst other routes of administration owing to higher usage for treatment of tuberculosis, MDR-TB, and XDR-TB. Use of second line anti tuberculosis drugs such as kanamycin & capreomycin by global organizations is attributive for generation of maximum revenue in this segment.
Human use for treatment of respiratory disorders accounted for largest share in applications segment owing to rise in global incidence of tuberculosis. Furthermore, other bacterial infections of respiratory tract that can be treated using aminoglycoside class of antibiotics are anticipated to contribute for expected growth in this segment.
Veterinary treatment is expected to boost industrial growth in the coming years owing to higher incidence of animal diseases outbreaks. However, these drugs have restrictive regulations for administration to food-producing animals as it may lead to toxic effects and resistance development on humans after consumption of animal originated food.
Asia Pacific was the largest market, accounting for over 40% of revenue in aminoglycoside industry owing to, the presence of market players in this region coupled with higher rate of tuberculosis incidences herein.
South Africa spearheaded growth in the MEA market. The presence of relatively higher demand and consumption of injectable solutions in this region because of increase in incidence rate of MDR-TB and other drug resistant infections are some regional growth drivers.
Key participants of the aminoglycoside market include Vega Pharma Ltd., Kremoint Pharma Pvt. Ltd, Xian Wison Biological Technology Co., Ltd., Jiangxi Bolai Pharmacy Co., Ltd., Medson Pharmaceuticals, Hangzhou Uniwise International Co., Ltd., Yi Chang Veterinary Medicine Factory, HuvePharma, and Medico Remedies Pvt. Ltd.
Market players are involved in the development of products with newer formulations and lesser side effects in order to treat eradicate bacterial infections that are resistant to other class of antibiotics.

Organic Personal Care Market Size Worth $25.11 Billion By 2025

The global organic personal care market size is projected to reach USD 25.11 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 9.4% during the forecast period. Rising R&D expenditure to introduce improved plant and animal extracts into various products is expected to promote the demand. Furthermore, regulations promoting the use of organic materials in personal care industry is likely to propel the growth.

Growing demand for organic products has resulted in an increase in their availability in supermarkets, malls, and drugstores. In addition, growth in online market where consumers can access a wide range of products from any part of the world has been a primary reason for increase in accessibility and is expected to remain a key contributing factor for the market growth over the forecast period. Online stores also give consumers the opportunity to gain access to products that would otherwise not be available in local stores and malls, which has made them especially popular in emerging markets.

The market includes a variety of products such as hair care, oral care, skin care, cosmetics, and others. Other product segments include oils, body sprays, perfumes, and masculine and feminine hygiene products. Growing popularity of natural products is the key factor driving demand. Growth product distribution channels in urban areas has made these products easily accessible to consumers. As these products reflect the growing aspirations of better hygiene, health, and beauty in modern times, their adoption has exhibited significant growth. Furthermore, with the introduction of products such as flosses and mouthwashes, the demand for organic oral care products is expected to increase.

Demand for products that are free from synthetic fragrances, preservatives, parabens, petrochemicals, and harsh cleaners such as sodium lauryl sulfate has been on the rise over the past few years. Numerous major market players are involved in manufacturing a variety of personal care products, such as sunscreens, body lotions, shampoos, scrubs, anti-aging creams, makeup removers, masks and exfoliators, eye care products, lip care products, BB creams, face oils, and cleansers/toners.

North America was the largest regional segment of the organic personal care market in 2018, and is expected to continue leading over the forecast period, on account of rising demand for safe and natural products. Over the past few years, companies have been introducing new and innovative products specifically designed to cater to the various consumer needs. Major players such as L’Oréal, The Body Shop, and Estée Lauder have launched new organic products that target aging population.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/organic-personal-care-market

Further key findings from the report suggest:

Skin care application held the leading market share of over 33.7% in terms of revenue in 2018, owing to the ability of organic ingredients to impart antioxidation properties and improve skin health
The U.S. organic personal care market is anticipated to exceed USD 7.74 billion by 2025 owing to the presence of various manufacturers in the country
The global market is highly competitive with the presence of a number of multinational companies with wide product portfolios. Some of the key companies present in the market include Aveda Corporation, Burt’s Bees, and The Estée Lauder Companies Inc., among various others players.
The companies lay high emphasis on expanding their presence global scale, in an attempt to increase market shares and to drive revenues. For instance, Estee Lauder has acquired various companies such as BECCA Cosmetics, Too Faced, and Editions de Parfums Frédéric Malle, over the past few years to expand its product portfolio.

Hormone Replacement Therapy Market Worth $28.4 Billion By 2022

Global hormone replacement therapy market is expected to reach USD 28.4 billion by 2022, according to a new report by Grand View Research, Inc. Increasing geriatric and neonatal population base, growing cases of hormonal imbalances, and large presence of unmet healthcare needs in emerging economies are some vital impact rendering drivers.

Estrogen replacement therapy dominated the market in 2015. Moreover, the rising number of women reaching the menopausal age is expected to drive the demand for these treatments over the forecast period.

Furthermore, rise in premature births that lead to genital disorders and slower rate of growth in these neonates are anticipated to fuel the demand for growth hormone therapy. According to statistics provided by the CDC, over 15 million babies were born preterm in 2014 annually. This number is anticipated to rise over the next seven years and become a leading cause for disabilities, illnesses, arrested development, and mortality.

To request a sample copy:
http://www.grandviewresearch.com/industry-analysis/hormone-replacement-therapy-market

Further key findings from the study suggest:

Estrogen therapy is expected to dominate the product segment and hold over 50.0% of the market share by 2022. This growth can be attributed to the increasing focus of healthcare bodies such as the Women’s Health Initiative, The North America Menopause Society, and The British Menopause Society, on providing safe replacement therapy.
The parenteral route of administration is commonly used for delivery of drugs such as Nutropin, Signifor, Genotropin, and Tev-Tropin. Other routes such as pen-based delivery systems and implants are gaining popularity owing to higher patient comfort and ease-of-use. Furthermore, technological advancements in the field providing higher bioavailability of drug and needle-free administration are predicted to positively impact growth.
Menopause and their vasomotor symptoms are expected to be the most prevalent disease over the forecast period owing to increasing number of women approaching the menopausal age. The segment is predicted to hold about 40.0% of the market share by 2022.
North America, particularly the U.S. dominated the market and held about 35.0% of the total revenue in 2015. Existence of well-regulated healthcare system and presence of a large pool of target population are a few factors that promote growth. Countries such as South Africa, China, India, and Brazil are anticipated to witness lucrative growth over the forecast period, with China predicted to have the fastest growth of over 10.0%.
Some key companies catering to hormone replacement therapies include Pfizer, Inc., Merck Serono, Novo Nordisk, Eli Lilly, Bayer Healthcare, Mylan Laboratories, Amgen, Novartis, and Genentech. Introduction of new formulations and development of innovative drug delivery systems are expected to be a few initiatives taken by these players over the forecast period.